

Interface and Formulary Update - Issue 39

November 2025

Key messages from November 2025 TAG meetings - (ratified by Medicines Optimisation Programme Board)

Commissioning Review – Guidance on the prescribing of shower and swim protection pouches

- Currently **BLACK** – Not commissioned for local use
- Commissioning Statement published on [KNoW](#)
- Netformulary entry **updated**
- Reminder in ‘news’ sections on **Netformulary** and **Connect NoW**
- Letter sent to manufacturer
- **BLACK** classification includes all brands (e.g. Cath Dry Dressing, Independence easy access / wound protection / collection pouches, or LINC catheter shower pouches) as well as related products (e.g. Independence No Sting Barrier Film wipes). Brand and product lists are not exhaustive.

Commissioning Review - Peristeen Light – low volume transanal irrigation device

- New product
- Requests from Continence team to prescribe
- Not yet commissioned for local use
- **BLUE** classification pending formulary application

Formulary Review – Continuous Blood Glucose Monitoring

- Freestyle Libre® 2 and 3, and Dexcom ONE and ONE+ have been amended to **Amber Advice** - Primary care initiation following specialist recommendation

Traffic Light Additions / Updates (to be read in conjunction with [TAG Agreement document](#))

RED	TA937 – December 2023, updated October 2025 Targeted-release budesonide (Kinpeygo®) for treating primary IgA nephropathy
	TA1101 – October 2025 Garadacimab (Andembry®) for preventing recurrent attacks of hereditary angioedema in people 12 years and over
	TA1103 – October 2025 Lorlatinib (Lorviqua®) for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitor (Replaced TA909)
	TA1104 – October 2025 Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal)
BLACK	TA1105 – October 2025 Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal)
	TA1102 – October 2025 Iptacopan for treating complement 3 glomerulopathy (terminated appraisal)
NICE - Approved	TA1074 – June 2025, updated October 2025 Sparsentan (Filspari®) for treating primary IgA nephropathy

Useful Information	
Next TAG meeting	Wednesday 7th January 2026
Deadline for agenda items	Tuesday 30th December 2025
Netformulary	Norfolk and Waveney Formulary (norfolkandwaveneyformulary.nhs.uk)
Knowledge NoW – MO Team pages	Prescribing, Pharmacy and Medicines Optimisation - Knowledge NoW (nwknowledgenow.nhs.uk)
TAG Guidance	Therapeutic Advisory Group (TAG) and Commissioning - Knowledge NoW (nwknowledgenow.nhs.uk)
Shared Care Agreements	Shared Care Agreements - Knowledge NoW (nwknowledgenow.nhs.uk)
Pathways and Prescribing Guidance	Pathways and Prescribing Guidance - Knowledge NoW (nwknowledgenow.nhs.uk)
Practice Support	Practice Support - Knowledge NoW (nwknowledgenow.nhs.uk)
Useful Links	Useful Links - Knowledge NoW (nwknowledgenow.nhs.uk)
<ul style="list-style-type: none"> • Please remember to check both KNoW and Netformulary for regular formulary updates • If you have any interface or formulary queries, please send to the inbox - nwicb.medsqueries@nhs.net 	